Genetic Variants ID Treatment Response in Psoriasis

This article originally appeared here.
Share this content:
Genetic Variants ID Treatment Response in Psoriasis
Genetic Variants ID Treatment Response in Psoriasis

TUESDAY, May 10, 2016 (HealthDay News) -- Genetic variants have been identified in psoriasis patients that correlate with anti-tumor necrosis factor (TNF)-α treatment response, according to research published online April 30 in the Journal of Dermatology.

Rika Nishikawa, M.D., from the Kobe University Graduate School of Medicine in Japan, and colleagues examined clinical biomarkers for predicting therapeutic responses or to serve as new drug targets for refractory psoriasis. Sixty-five patients were followed after initiating anti-TNF-α therapy. A genome-wide association study was conducted and correlations between single nucleotide polymorphisms (SNPs) and changes in the Psoriasis Area and Severity Index were examined after 12 weeks of treatment.

The researchers identified 731,442 SNPs in the psoriasis patients who were treated with adalimumab or infliximab. Ten SNPs, including those in JAG2 and ADRA2A, correlated with treatment responses to anti-TNF-α agents. Other SNPs were identified that showed potential correlations with anti-TNF-α treatment response; of these, rs11096957 on TLR10 was previously reported to be linked to treatment responses to TNF-α-inhibitors.

"The novel loci and reference list of candidate SNP highlighted herein warrant further investigation for pharmacogenetic studies of psoriasis patients," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »